{"id":"W2089664277","doi":"10.3816/clc.2008.n.037","title":"An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial","year":2008,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gemcitabine; Medicine; Oncology; Internal medicine; Cisplatin; Erlotinib Hydrochloride; Clinical endpoint; Chemotherapy; Progression-free survival; Randomized controlled trial; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005796181,0.002901165,0.004309923,0.0004956302,0.000891241,0.001831127,0.001472468,0.002181804,0.00542928],"category_scores_gemma":[0.004514854,0.0009492709,0.00307227,0.0006715613,0.002481082,0.002006122,0.0007557379,0.007027716,0.001488623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002269105,"about_ca_system_score_gemma":0.003119713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001973627,"about_ca_topic_score_gemma":0.004651433,"domain_scores_codex":[0.9980029,0.001226663,0.0000763491,0.0003260566,0.0001025458,0.0002654327],"domain_scores_gemma":[0.9978479,0.0005586454,0.0004980834,0.0002979574,0.0001529093,0.0006445696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9820459,0.005405936,0.0005150422,0.0001705151,0.0008990483,0.00001734945,0.00004365763,0.0004965203,0.0011265,0.0001624631,0.001355838,0.007761109],"study_design_scores_gemma":[0.9654475,0.03173948,0.001017377,0.00001503686,0.0005726513,0.000023038,0.00002154518,0.0002820693,0.0002457293,0.0001696395,0.0004502188,0.00001570913],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9735151,0.003639227,0.001928153,0.002804155,0.001262407,0.008754021,0.002660238,0.0002634584,0.005173278],"genre_scores_gemma":[0.9756615,0.001939889,0.00353907,0.002967916,0.0006983927,0.007477417,0.003022746,0.0001076917,0.004585381],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.005796181,"threshold_uncertainty_score":0.03065348,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03595857253129783,"score_gpt":0.4227494391711765,"score_spread":0.3867908666398787,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}